Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2025 ,inter alia, to consider and approve Un-audited financial results ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd has informed BSE that its Board of Directors will meet on Friday, August 8, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26). The company has also closed the trading window for its equity shares for all designated persons and their immediate relatives, in line with insider trading rules. The window will reopen 48 hours after the results are declared. This is a routine regulatory intimation under SEBI LODR Regulation 29, and no actual financial numbers have been disclosed yet.
Investors should await the Q1 FY26 results on August 8, 2025, for actual performance data. Until then, no material impact on the stock can be assessed from this notice alone. The closed trading window means insiders cannot trade until results are announced.